Future studies investigating the heterogeneous effect of statin by common somatic mutations in KRAS, TP53, CDK2N2A, SMAD4, are warranted to elucidate the mechanisms by which statin could impact tumor’s growth, invasion and metastasis. Here, TP53 is linked to neoplasm.